Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
- B. Chapuy, C. Stewart, M. Shipp
- Biology, MedicineNature Network Boston
- 30 April 2018
A comprehensive genetic analysis of 304 primary DLBCLs identified low-frequency alterations, captured recurrent mutations, somatic copy number alterations, and structural variants, and defined coordinate signatures in patients with available outcome data to provide a roadmap for an actionableDLBCL classification.
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera…
- M. Pfreundschuh, L. Trümper, M. Loeffler
- MedicineThe Lancet Oncology
- 1 May 2006
Human neoplasms elicit multiple specific immune responses in the autologous host.
- U. Şahin, O. Türeci, M. Pfreundschuh
- Biology, MedicineProceedings of the National Academy of Sciences…
- 5 December 1995
The unexpected frequency of human tumor antigens indicates that human neoplasms elicit multiple specific immune responses in the autologous host and provides diagnostic and therapeutic approaches to human cancer.
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
- E. Hoster, M. Dreyling, M. Unterhalt
- MedicineBlood
- 16 November 2006
The MIPI is the first prognostic index particularly suited for MCL patients and may serve as an important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL.
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.
- Yao-Tseng Chen, M. Scanlan, L. Old
- Biology, MedicineProceedings of the National Academy of Sciences…
- 4 March 1997
R reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma, which indicates that it belongs to an expanding family of immunogenic testicular antigens.
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
- P. Sonneveld, I. Schmidt-Wolf, H. Goldschmidt
- Medicine, BiologyJournal of Clinical Oncology
- 20 August 2012
Bortezomib during induction and maintenance improves CR and achieves superior PFS and OS and a benefit was also observed in patients with deletion 17p13.
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
- M. Pfreundschuh, J. Schubert, M. Loeffler
- MedicineThe Lancet Oncology
- 1 February 2008
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
- H. Tilly, M. Gomes da Silva, M. Ladetto
- MedicineAnnals of Oncology
- 1 October 2012
This work presents the results of a double-blind, placebo-controlled study conducted at the University of Southampton over a two-week period in June and July of last year that demonstrated clear trends in prognosis for breast cancer in smokers and women with a history of smoking.
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
- V. Diehl, J. Franklin, M. Loeffler
- MedicineNew England Journal of Medicine
- 12 June 2003
Investigation of three combinations of chemotherapy for advanced Hodgkin's disease found increased-dose BEACOPP resulted in better tumor control and overall survival than did COPP-ABVD and standard BEACopP.
NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity
- L. Wojnowski, B. Kulle, G. Hasenfuss
- Biology, MedicineCirculation
- 13 December 2005
Genetic variants in doxorubicin transport and free radical metabolism may modulate the individual risk to develop ACT.
...
...